Pembrolizumab was the first ICI agent to be approved as 1 L treatment (2016) for advanced NSCLC patients without targetable mutations and a PD-L1 expression level ≥50% [4], based on results from the pivotal Keynote-024 trial [6, 7]. Here, CD274 is linked to non-small cell lung carcinoma.